In conclusion, our preliminary studies indicate that Evobrutinib can inhibit M1 microglial polarization via the TLR4/MyD88/NF-κB pathway, mitigate neuroinflammation, and potentially serve as a therapeutic agent for ischemic stroke. Here, MYD88 is linked to ischemic stroke.